Loading…
Daxor Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▲ +1.9% over 5Y.
today you would have $942.64▼ -5.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2011 | 2010 |
|---|---|---|---|
| Year-end price | $9.10 | $9.25 | |
| P/E | — | — | 7.9x |
| P/S | — | 26.4x | 24.8x |
| P/B | — | 1.1x | 0.8x |
| EPS | -$1.70 | $1.17 | |
| Dividend yield | — | 2.75% | 10.81% |
| Payout | — |
Not shown for closed-end funds and BDCs. The methods assume operating profit, and a fund’s earnings per share are capital gains on its portfolio plus interest income — running them through Graham or a discounted cash flow produces a number that looks like a valuation and means nothing. What matters for a fund is its price against net asset value, which this site does not track.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| XLOXilio Therapeutics, Inc. | $9.00 | — | 1.2x | — | -55.03% | $59.22M |
| IMAImageneBio, Inc. | $5.34 | — | 0.4x | — | -82.68% | $60.74M |
| INKTMiNK Therapeutics, Inc. | $11.43 | — | — | — | — | $58.32M |
| HYPDHyperion Defi Inc | $3.92 |
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Company description provided by Yahoo Finance.
| — |
| 85.47% |
| Profit margin | — | -496.81% | 314.60% |
| ROE | — | -19.84% | 10.57% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.6x |
| — |
| 9.55% |
| $60.84M |
| SRTSSensus Healthcare, Inc. | $3.52 | — | 1.6x | — | -34.83% | $57.95M |
| TLPHTalphera Inc | $1.20 | — | 3.3x | — | -143.36% | $62.29M |